Novavax (LTS:0UP6) Total Liabilities : $2,221 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Novavax Total Liabilities?

Novavax's Total Liabilities for the quarter that ended in Mar. 2024 was $2,221 Mil.

Novavax's quarterly Total Liabilities increased from Sep. 2023 ($2,335.51 Mil) to Dec. 2023 ($2,514.42 Mil) but then declined from Dec. 2023 ($2,514.42 Mil) to Mar. 2024 ($2,220.62 Mil).

Novavax's annual Total Liabilities declined from Dec. 2021 ($2,928.43 Mil) to Dec. 2022 ($2,892.76 Mil) and declined from Dec. 2022 ($2,892.76 Mil) to Dec. 2023 ($2,514.42 Mil).

Novavax Total Liabilities Historical Data

The historical data trend for Novavax's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Total Liabilities Chart

Novavax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

358.97

955.27

2,928.43

2,892.76

2,514.42

Novavax Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															2,438.28	2,439.57	2,335.51	2,514.42	2,220.62

Novavax Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Novavax's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1635.138	+	(223.939	+	33.13
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	622.21	+	0)
	=	2,514

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1797.49	-	-716.927
	=	2,514

Novavax's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	804.382	+	(223.041	+	351.722
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	841.473	+	0)
	=	2,221

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1353.534	-	-867.084
	=	2,221

Novavax Total Liabilities Related Terms

Thank you for viewing the detailed overview of Novavax's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax (LTS:0UP6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (LTS:0UP6) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NVAX:USA NVAX:Mexico NVV1:Germany

Address

21 Firstfield Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Novavax (LTS:0UP6) Headlines

No Headlines